Commerce Bank
VKTX icon

Commerce Bank’s Viking Therapeutics VKTX Stock Holding History

Commerce Bank’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$449K Sell
13,761
-848
-6% -$29.4K ﹤0.01% 974
2026
Q2 		$570K Hold
14,609
– – ﹤0.01% 924
2026
Q1 		$475K Sell
14,609
-158
-1% -$5.08K ﹤0.01% 955
2025
Q4 		$520K Buy
14,767
+680
+5% +$24.1K ﹤0.01% 867
2025
Q3 		$370K Hold
14,087
– – ﹤0.01% 984
2025
Q2 		$373K Buy
+14,087
New +$371K ﹤0.01% 959

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Commerce Bank's VKTX Position: Q3 2026 in Review

Commerce Bank reduced its Viking Therapeutics (VKTX) stake by 5.8% in Q3 2026, selling an estimated $29.4K and leaving 13,761 shares worth $449K. The position accounts for ﹤0.01% of the portfolio, ranked #974.

Commerce Bank first reported a position in VKTX in Q2 2025 and has held it in 6 quarters since. The position peaked at $570K in Q2 2026. 322 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.

  • Commerce Bank held 13,761 shares of Viking Therapeutics worth $449K as of Q3 2026.
  • Commerce Bank sold 848 Viking Therapeutics shares in Q3 2026, an estimated $29.4K.
  • Viking Therapeutics made up ﹤0.01% of Commerce Bank's portfolio in Q3 2026, its #974 holding.
  • Commerce Bank first reported a position in Viking Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Commerce Bank's Viking Therapeutics position peaked at $570K in Q2 2026.
  • 322 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.

Based on Commerce Bank's 13F filing for Q3 2026, filed 12 Nov 2026.